Personalized medical device for the diagnosis and treatment of ADHD based on EEG biomarkers and Neurofeedback Training

Información del proyecto

NEWROFEED

Identificador del acuerdo de subvención: 684809

DOI

10.3030/684809

Proyecto cerrado

Fecha de la firma de la CE 11 Octubre 2015

Fecha de inicio 1 Octubre 2015

Fecha de finalización 31 Marzo 2018

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 3 600 632,50

Aportación de la UE

€ 3 600 632,50

Coordinado por

MENSIA TECHNOLOGIES
France

Objetivo

NEWROFEED aims at setting a new standard of care for children suffering from Attention Deficit Hyperactivity Disorder (ADHD). ADHD@Home is the diagnosis and treatment medical device, developed by Mensia in project NEWROFEED, to achieve this goal. In order to optimise success rates, ADHD@Home is based on an EEG biomarker-based personalised medicine approach to treat ADHD children with state-of-the-art personalized Neurofeedback Training. This patient-centered solution is delivered at home, with supervision by ADHD specialists. As an efficacious alternative to treatment by psychoactive medication, the expected clinical outcomes include normalized social behaviour and improved school performance.
ADHD@Home delivers physiological lasting normalization of brain activity, using the child’s endogenous neuronal plasticity, to resolve his or her attention and hyperactivity problems. Its unique technology and design enable it to achieve two critical clinical objectives:
1. To identify the root cause of the ADHD for a given child by quantifying, in real-time, deviations in EEG oscillation biomarkers allowing the clinician to select and adjust the Neurofeedback protocols.
2. To deliver the personalized Neurofeedback protocols on an affordable and user-friendly device, enabling optimal training at home under remote medical supervision.
This clinical breakthrough is made possible by Mensia’s cloud-based real time quantitative EEG analysis technology. ADHD@Home will be validated for efficacy in the NEWROFEED Clinical Trial. This will pave the way for a successful commercial launch in 2018 to deliver on our promise of efficacious physiological treatment for millions of ADHD children.
Thanks to NEWROFEED, Mensia will become a world leader in the field of EEG-based personalised treatment of Central Nervous System disorders; capitalizing on the clinical success of its ADHD@Home device that will generate 65M€ in cumulative revenues by 2022.

Ámbito científico (EuroSciVoc)

• ciencias naturales › ciencias biológicas › neurobiología
• ciencias médicas y de la salud › ciencias de la salud › salud pública y medio ambiental
• ciencias médicas y de la salud › medicina clínica › psiquiatría
• ciencias médicas y de la salud › medicina básica › farmacología y farmacia › medicamento
• ciencias médicas y de la salud › ciencias de la salud › medicina personalizada

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
  
• H2020-EU.3.1.3. - Treating and managing disease
  

Tema(s)

• PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
  

Régimen de financiación

SME-2 - SME instrument phase 2

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Coordinador

MENSIA TECHNOLOGIES

• Aportación neta de la UEn: € 3 600 632,50
• Dirección: PLACE DU GRANIER ; 35571 CHANTEPIE ; Francia
• Pyme Sí:
  Región
  Bretagne › Bretagne › Ille-et-Vilaine
• Región: Bretagne › Bretagne › Ille-et-Vilaine
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 3 600 632,50